94 related articles for article (PubMed ID: 22037511)
21. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
22. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
van Gelder T; Hesselink DA
Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
[TBL] [Abstract][Full Text] [Related]
23. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
[TBL] [Abstract][Full Text] [Related]
24. Choosing the right dose of tacrolimus.
Lancia P; Jacqz-Aigrain E; Zhao W
Arch Dis Child; 2015 Apr; 100(4):406-13. PubMed ID: 25416736
[TBL] [Abstract][Full Text] [Related]
25. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients.
Barrera-Pulido L; Aguilera-García I; Docobo-Pérez F; Alamo-Martínez JM; Pareja-Ciuró F; Nuñez-Roldán A; Gómez-Bravo MA; Bernardos-Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2949-51. PubMed ID: 19010156
[TBL] [Abstract][Full Text] [Related]
26. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
Zheng H; Zeevi A; Schuetz E; Lamba J; McCurry K; Griffith BP; Webber S; Ristich J; Dauber J; Iacono A; Grgurich W; Zaldonis D; McDade K; Zhang J; Burckart GJ
J Clin Pharmacol; 2004 Feb; 44(2):135-40. PubMed ID: 14747421
[TBL] [Abstract][Full Text] [Related]
27. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations.
Wehland M; Bauer S; Brakemeier S; Burgwinkel P; Glander P; Kreutz R; Lorkowski C; Slowinski T; Neumayer HH; Budde K
Pharmacogenet Genomics; 2011 Apr; 21(4):179-84. PubMed ID: 20818295
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
Thervet E; Legendre C; Beaune P; Anglicheau D
Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs.
Picard N; Bergan S; Marquet P; van Gelder T; Wallemacq P; Hesselink DA; Haufroid V
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S57-69. PubMed ID: 26469711
[TBL] [Abstract][Full Text] [Related]
30. Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?
MacPhee IA; Fredericks S; Holt DW
Expert Opin Pharmacother; 2005 Dec; 6(15):2593-605. PubMed ID: 16316299
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of tacrolimus-related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise.
Lin G; Zhang X; Zhang K; Han Y; Tan L; Li J
J Clin Lab Anal; 2018 Oct; 32(8):e22563. PubMed ID: 29708622
[TBL] [Abstract][Full Text] [Related]
32. Clinical implications of CYP3A polymorphisms.
Wojnowski L; Kamdem LK
Expert Opin Drug Metab Toxicol; 2006 Apr; 2(2):171-82. PubMed ID: 16866606
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.
Ekbal NJ; Holt DW; Macphee IA
Pharmacogenomics; 2008 May; 9(5):585-96. PubMed ID: 18466104
[TBL] [Abstract][Full Text] [Related]
34. Consideration of the ethnic prevalence of genotypes in the clinical use of tacrolimus.
Andrews LM; De Winter BC; Van Gelder T; Hesselink DA
Pharmacogenomics; 2016 Nov; 17(16):1737-1740. PubMed ID: 27790923
[No Abstract] [Full Text] [Related]
35. [Effect of genetic polymorphism on disposition of calcineurin inhibitors in solid organ transplantation].
Li D; Zhu L; Ye Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 35(9):1018-22. PubMed ID: 20871172
[TBL] [Abstract][Full Text] [Related]
36. Current progress of tacrolimus dosing in solid organ transplant recipients: Pharmacogenetic considerations.
Zhang X; Lin G; Tan L; Li J
Biomed Pharmacother; 2018 Jun; 102():107-114. PubMed ID: 29550633
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a rapid and reliable real-time PCR method for CYP3A5 genotyping.
Eidens M; Weise A; Klemm M; Fleischer M; Prause S
Clin Lab; 2015; 61(3-4):353-62. PubMed ID: 25975003
[TBL] [Abstract][Full Text] [Related]
38. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.
MacPhee IA; Holt DW
Transplantation; 2008 Jan; 85(2):163-5. PubMed ID: 18212618
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of 6β-Hydroxycortisol and 6β-Hydroxycortisone as Biomarkers for Cytochrome P450 3A Activity: Insight into Their Predictive Value for Estimating Oral Immunosuppressant Metabolism.
Luo X; Zheng L; Cai N; Liu Q; Yang S; He X; Cheng Z
J Pharm Sci; 2015 Oct; 104(10):3578-86. PubMed ID: 26150050
[TBL] [Abstract][Full Text] [Related]
40. Update on the clinical pharmacogenomics of organ transplantation.
Burckart GJ; Amur S
Pharmacogenomics; 2010 Feb; 11(2):227-36. PubMed ID: 20136361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
